• Abstract
• Full-Text PDF [365 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• PubMed/Medline
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Yang, J
• Li, M
• Shen, X
• Liu, S
• [+] on Google Scholar
• Yang, J
• Li, M
• Shen, X
• Liu, S
• [+] on PubMed
• Yang, J
• Li, M
• Shen, X
• Liu, S

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Viruses 2013, 5(1), 352-373; doi:10.3390/v5010352

Review

Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin

Jie Yang ¹ , Minmin Li ² , Xintian Shen ¹  and Shuwen Liu ^1,*

¹ School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China ² Department of Clinical Laboratory, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China

* Author to whom correspondence should be addressed.

Received: 14 December 2012; in revised form: 17 January 2013 / Accepted: 21 January 2013 / Published: 22 January 2013

(This article belongs to the Special Issue Viral Entry Inhibitors)

Download PDF Full-Text [365 KB, uploaded 22 January 2013 11:35 CET]

Abstract: Influenza A virus (IAV) has caused seasonal influenza epidemics and influenza pandemics, which resulted in serious threat to public health and socioeconomic impacts. Until now, only 5 drugs belong to two categories are used for prophylaxis and treatment of IAV infection. Hemagglutinin (HA), the envelope glycoprotein of IAV, plays a critical role in viral binding, fusion and entry. Therefore, HA is an attractive target for developing anti‑IAV drugs to block the entry step of IAV infection. Here we reviewed the recent progress in the study of conformational changes of HA during viral fusion process and the development of HA-based IAV entry inhibitors, which may provide a new choice for controlling future influenza pandemics.

Keywords: influenza A virus; hemagglutinin; viral entry; antiviral drugs

Article Statistics

Cite This Article